Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: $REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regeneron Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regeneron Pharmaceuticals's position in the market.
Regeneron Pharmaceuticals and Society for Science awarded over $9 million to high school scientists at the 2024 Regeneron International Science and Engineering Fair (ISEF), the world's largest pre-college STEM competition.
Grace Sun won the top $75,000 award for her innovative organic electrochemical transistor. Michelle Wei and Krish Pai each received $50,000 for their respective projects in software efficiency and plastic biodegradation.
The competition, held in Tarrytown, NY and Washington, D.C., featured nearly 2,000 young scientists from 49 U.S. states and almost 70 countries. Other notable awards included $50,000 for a microplastics filtration system and $10,000 for a dementia multi-sensory therapy app.
Since 2020, Regeneron has provided STEM experiences to about 2.4 million students, aiming for 2.5 million by 2025. The fair emphasized the importance of fostering next-generation STEM leaders to tackle global challenges.
Regeneron Pharmaceuticals, Inc. and Sanofi's sBLA for Dupixent® (dupilumab) in adolescents with Chronic Rhinosinusitis with Nasal Polyposis has been accepted for FDA Priority Review. If approved, Dupixent would be the first treatment in the U.S. for this condition in adolescents aged 12-17 years. The target action date for the FDA decision is September 15, 2024. The sBLA is based on positive pivotal trials in adults that showed Dupixent improved nasal congestion, polyp size, sense of smell, and reduced the need for systemic corticosteroids or surgery.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced positive preliminary data from the ongoing Phase 1/2 CHORD trial, showing significant hearing improvements in children with genetic deafness who received the investigational gene therapy DB-OTO. One child achieved normal hearing levels within 24 weeks, while another showed initial improvements at 6 weeks. The results were presented at the ASGCT conference, highlighting the potential of DB-OTO as a treatment for otoferlin-related deafness.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will be participating in investor conferences including the RBC Capital Markets Global Healthcare Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 45th Annual Global Healthcare Conference. The webcasts can be accessed on the company's website, with replays available for 30 days.
Regeneron reported first quarter 2024 financial results with revenues decreasing 1% to $3.15 billion; excluding Ronapreve, revenues increased 7%. Dupixent global net sales rose 24% to $3.08 billion, EYLEA U.S. net sales were $1.40 billion, and Libtayo global net sales increased 45% to $264 million. The company announced a $3.0 billion share repurchase program. Regeneron is progressing well in delivering medicines, advancing its pipeline, and pursuing cutting-edge science, particularly in retinal diseases, oncology, and potential regulatory approvals. Financially, GAAP net income decreased by 12% and non-GAAP diluted EPS decreased by 5%. The company is focusing on innovation and returned $298 million to shareholders through share repurchases.
Regeneron Pharmaceuticals, Inc. announced positive long-term results from the EYLEA HD clinical program, showcasing durable efficacy and safety in patients with retinal diseases. The data presented at ARVO highlight the potential of EYLEA HD as a new standard of care for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Notable presentations include results from the PHOTON and PULSAR trials, demonstrating maintained visual improvements with EYLEA HD.
